Evidence map›Paper›PMID 28357123›Full record

ArticlePharmacology research & perspectives2017

Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016.

Ibrahim A Oreagba, Kazeem A Oshikoya, Comfort Ogar, Abiodun O Adefurin, Ali Ibrahim, Olufunsho Awodele, Yetunde Oni

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A Saudi Arabian Public Health Perspective of Tuberculosis.International journal of environmental research and public health · 2021
    Review
  5. Article
  6. Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.European respiratory review : an official journal of the European Respiratory Society · 2019
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Ibrahim A OreagbaPharmacology, Therapeutics and Toxicology Department College of Medicine University of Lagos Idiaraba Lagos Nigeria.
Kazeem A OshikoyaPharmacology Department Lagos State University College of Medicine Ikeja Lagos Nigeria.ORCID 0000-0003-3662-8476
Comfort OgarNational Pharmacovigilance Centre National Agency for Food and Drug Administration and Control Abuja Nigeria.
Abiodun O AdefurinDepartment of Internal Medicine Meharry Medical College 1005 Dr. D.B. Todd Jr. Blvd. Nashville Tennessee.
Ali IbrahimNational Pharmacovigilance Centre National Agency for Food and Drug Administration and Control Abuja Nigeria.
Olufunsho AwodelePharmacology, Therapeutics and Toxicology Department College of Medicine University of Lagos Idiaraba Lagos Nigeria.
Yetunde OniNational Pharmacovigilance Centre National Agency for Food and Drug Administration and Control Abuja Nigeria.
Food and Drug Administration · THUniversity of Lagos · NGLagos State University · NGMeharry Medical College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adverse drug reactions (ADRs) recorded in national pharmacovigilance databases in developed countries have been analyzed. However, adverse reactions to fluoroquinolones were observed globally despite their wide use and safety concerns. We provided information on the pattern of adverse reactions to fluoroquinolones reported spontaneously to the National Pharmacovigilance Centre (NPC), Nigeria. ADRs to fluoroquinolones reported to the NPC, over a period of 12 years, were analyzed. Evaluation was done for annual reports, age and gender of patients, type of reporter, suspected fluoroquinolones and adverse reactions, onset and outcome of ADRs, and causality. A total of 18527 ADR reports were received by the NPC. Antibiotics accounted for 1371(7.4%) of the total reports and fluoroquinolones accounted for 256 (18.7%) cases. A total of 540 ADRs due to fluoroquinolones was experienced by the patients. Multiple ADRs were experienced by 165 (65%) patients. Norfloxacin (2; 0.8%), moxifloxacin (3; 1.2%), ofloxacin (10; 3.9%), ciprofloxacin (112; 43.8%), and levofloxacin (129; 50.4%) were responsible for the ADRs. Neurological disorders (121; 22.4%), gastrointestinal disorders (118; 21.9%), and skin-appendage disorders (116; 21.5%) were the most reported ADRs, while pruritus (41; 7.6%), abdominal pain (34; 6.3%), vomiting (34; 6.3%), and skin rash (27; 5.0%) were the most frequently reported specific ADRs. Thirty-four (6.4%) patients experienced serious ADRs. Fluoroquinolones accounted for a small but significant proportion of ADRs spontaneously reported to the NPC in Nigeria. Ciprofloxacin and levofloxacin were the two most culpable fluoroquinolones due to their inappropriate use or increased use in multi-drug resistant tuberculosis (MDR-TB) treatment.

Indexed as

Adverse reactionsdatabasefluoroquinolonesNigeriapharmacovigilancespontaneous reports

Identifiers

PMID28357123
PMCPMC5368961
OpenAlexW2587939552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.